Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIVIGNO-2 first-line advanced hepatocellular carcinoma trial
2023-504600-28-00Phase 3Authorised
- Sponsor
- AbbVie Inc.
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of livmoniplimab and budigalimab in hepatocellular carcinoma (HCC) (3 arms), sponsored by AbbVie Inc. Primary endpoints: Best overall response and Overall survival. Planned start Apr 2024; status: authorised.
02
Drugs
livmoniplimabbudigalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2023-504600-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504600-28-00.